|
|
||||
        
|
Caleco Pharma Corp. (CAEH)
|
|||
|
Tuesday, October 13, 2009 – After Market Close Green Baron New “Stock Pick”
Caleco Pharma Corp. (BB: CAEH - $.18 per share) Common Shares Outstanding / 87.76 million Estimated Float / 4 million Current Market Cap / $15.8 million 52-Week High / $.29 per share 52-Week Low / $.025 per share Average Price / $.1748 (50-day) $.1233 (200-day) Average Volume / 79,900 (50-day) 53,000(200-day) Caleco Pharma Develops Proprietary, Naturally Sourced Products for Liver Health OTC Formulation Exhibits Remarkably Favorable Effects in Human Study Supported by Respected Members of Medical Community Caleco Also in Agreement with Puleva Biotech for the Introduction to Canada, the U.S. and Mexico of their Patented Pro-Biotic for the treatment and prevention of Mastitis; New Medical Product Already Proven and Authorized in Europe Green Baron Believes Caleco’s OTC Liver Health Formulation will be a Blockbuster; Potential Market in Billions of Dollars; Rx Version to Follow Most people know that your liver and kidneys are among your most vital organs. Liver problems can be caused through the use of prescribed pharmaceuticals (particularly drugs used to lower cholesterol like Lipitor and Crestor), heavy drinking, and stress. For people that have a serious virus like Hepatitis C or HIV, the reduction of viral loads in the liver is absolutely vital for survival. If a product were available for possible aid to liver health, or one that could markedly reduce viral loads in the liver for Hep-C carriers to normal, it would be considered a tremendous breakthrough. Today, we introduce you to the Company that believes it has a product that has already shown efficacy beyond anything else in the market, and is backed by established, respected medical professionals. The Green Baron Report is proud to announce that Caleco Pharma Corp. (BB: CAEH) is officially our 81st fully profiled focus “Stock Pick” and will be added to our storied list of previously profiled stocks on our home page. Results compiled from the most recent trade possible prior to dissemination of this report to the subsequent high will be monitored at www.thegreenbaron.com. Although we have very aggressive short and long term expectations for this stock, we still suggest our members try to accumulate as close to the profile price as possible. TRADING NOTES: CAEH is a fully reporting Bulletin Board stock that demonstrates strong market marker participation and usually a very tight spread of a half a cent or less. CAEH rallied in early September from about .10 per share to hit a high of .29 per share. A 50% pullback of the move up has left the stock on support of .18 per share. Volume can be active as indication by 497,000 shares that traded on October 1. Five trading days in the past two months have seen volume of over 200,000 shares. Average volume over the past 50 days is healthy at about 80,000 shares per day.
Caleco Pharma Corp. is focused on developing
products to treat moderate to severe liver
maladies, with over-the-counter formulations
that promote liver health, as well as Food
and Drug Administration (FDA) approved
pharmaceuticals that will treat chronic
viral infections of the liver. In addition,
Caleco will be developing together with Puleva
Biotech a patented pro-biotic
that has already been proven and authorized
in Europe to treat and prevent
Mastitis. There are several other products
in development, including hair treatment and
dermatological applications among others,
which have been tested and produced highly
positive results. The Green Baron Report believes Caleco is attractive to members right now due to the following reasons: 1. Proven study - Proprietary Caleco Pharma OTC formulations exhibited favorable effects to all 14 persons with Hepatitis C in a study over a six week period with no reported adverse side effects. 2. Support from Medical Professionals - Harry Fong, Phd, and Jim Metropoulos, M.D. represent two seasoned and respected industry professionals who believe in the product and its future. 3. Marketing Genius - Mr. Jim Sandino, Director, was strategic architect for the re-launch of Rogaine, the launch of Lamisil, and for numerous other successful efforts in every major therapeutic category for nearly every major Pharma company. 4. Market Size – The worldwide market interest in improved liver health is in the billions. Statistics show that 1 in every 12 people suffer from Hepatitis C. The market for Hepatitis C and HIV treatment alone is staggering. It should be noted that Hep-C and HIV are viruses that require continual on-going treatment. 5. Mastitis Product - Mastitis is an infection of the breast tissue that causes pain, swelling and redness of the breast that commonly affects women who are breast-feeding. Caleco intends to license a proven patented pro-biotic to generate revenues in the near-term. 6. Rx Formulation – The Company also plans to develop a synthetic prescription formulation with partnership opportunities for appropriate major Pharmaceutical manufacturers. Most investors have no idea that Caleco Pharma is now a publicly traded stock. We believe the word is just starting to get out about the potential of this company. CAEH is trading at a market cap that is a small fraction of the projected sales potential in year one for an OTC formulation of the liver product alone. The Mastitis product and other lifestyle product under license are expected to generate near-term revenues to fund additional studies for its liver health products. The Green Baron Report thinks Caleco Pharma (BB: CAEH) ought to rally to at least .50 per share by the end of October and at least $1.00 per share by year end. Members should seriously consider accumulating as close to our profile price as possible while it is still here. We expect several developments to occur over the near-term that will position CAEH for success. This one should be a huge winner! About Caleco Pharma Corp. Our business plan is to develop our proprietary technology designed to treat moderate to severe liver maladies, such as elevated liver enzymes and the Hepatitis C viral infection, (the "Liver Health Formula") as an over-the-counter product and as a United States Food and Drug Administration ("FDA") approved pharmaceutical. To date, our intellectual property covering the Liver Health Formula comprises of patent applications in the United States, Europe and Canada and four European Drug Master File applications, as well as a document issued by the European Health Authorities allowing the sale of the product “Lamirodosin” OTC, under the number Pl 1400/1 Lamiridosin, name which will be used in Europe and other areas. Caleco has filed U.S. provisional patent applications No. 60/901,602 filed February 13, 2007 and No. 61/000,550 filed October 26, 2007. Additionally, it filed World Intellectual Property Organization Application W0 2008/100547 A2 on February 13, 2008 and 4 EDMFs (European Drug Master Files) approved through Exxentia Puleva Biotech (its manufacturer and European Marketing Partner, (www.exxentia.com) and (http://www.pulevabiotech.com/pb/en/home.jsp) The Importance of Hepatitis C Virus (HCV) • Primary cause of liver cancer and liver transplant • HIV and Hepatitis C – #1 cause of death and hospitalizations in people living with HIV – Up to 1/3 of those living with HIV also have – HIV infection may promote HCV disease progression – Anti-HIV medications may cause hepatitis – HIV may impact HCV transmission (sex/perinatal) • Other Liver problems, elevated enzymes et al – All Statin Users (Lipitor, Crestor, etc.) at risk – Many Rx medications warn for liver impact – Lifestyle risks, e.g. heavy drinking, stress, etc. • Cost of Hep-C and Liver related issues in the billions Proprietary Caleco Pharma OTC formulations containing Lamium and Agrimonia exhibited favorable effects on liver health in 14 persons with Hepatitis C. See charts below:
Excerpts from Prof. Fong’s White Paper dated August 20, 2008 on the development of HP-201(Caleco’s product) · Based on research conducted in our laboratories, the anti-hepatitis/liver cirrhosis mitigation effects observed in the clinical study of LHF are most likely mediated by a direct anti-viral mechanism. · Structurally, HP-201, possessing four hydroxyl and one carbonyl groups, is an ideal lead compound for structural modification to produce more active candidates for drug development. · Seven of [13] congeners showed significant inhibition against the HCVpp infection · With the anti-HCV activity profiles having been demonstrated in two bioassay systems, and considering the observed clinical effects of the parent herbal formulation, I believe that there is a strong potential for the development of HP-201 and/or its congeners and derivatives into one or more anti-HCV therapeutic agents. · USA patent application* has been filed, and action has also been taken in filing for European patent(s) on these molecules. *USA patent application* has been filed, and action has also been taken in filing for European patent(s) on these molecules Additional supportive scientific medical opinion: Plutarco Restituyo, M.D. Gastroenterologist Center of Gastrodiagnosis and Specialties - Santo Domingo, Dominican Republic Doctor Restituyo supervised first clinical study on HP-201 Conclusions from his Clinical Study with the product
Current Hep-C Therapies Drug Based • Current Standard of Care: combination therapy for 24-48 weeks – Interferon (injected 3x week): an immune booster – Pegylated Interferon (injected 1x week): interferon w/ protein – Ribavirin (pill several times a day): an antiviral • Very Expensive, $25-$50,000 • Limited Effectiveness, about 50% on average • Severe side-effects, similar to chemo, severe impact on QOL OTC Based • As adjunctive/complimentary therapy only • Limited if any effectiveness—no clinical evidence of efficacy • Little awareness and self-limiting marketing Corporate Officers, Key Contributors and Advisors
John Boschert
Javier Benedi In the 1980s and early 1990s, Mr. Benedi gained considerable experience in the fields of real estate development and Investment operations. During this period, Mr. Benedi worked with LRC Technologies, LLC, Global Remediation, Inc., and Casino de Madrid (a privately owned club in Madrid). In 1994, he founded Societe de Participations et de Valeurs (SPV) in Luxembourg, a holding company engaged in Property Development, Metal trading, Leisure Industry and Finance activities. Mr. Benedi was the president and sole shareholder of SPV until 2000, when the assets of the company were sold. Since then, he has focused on the development, management and financing of various ventures.
James Sandino In healthcare, Mr. Sandino‘s credits include the re-launch of Rogaine, the launch of Lamisil, and numerous other successful efforts across every major therapeutic category for nearly every major Pharma company. From 1996 to 2001, Mr. Sandino was the President and CEO of Lowe Consumer Healthcare World Wide, a consumer focused healthcare marketing agency. Since 2001, Mr. Sandino has been the President and CEO of the Sandino Group, LLC, an independent marketing and business development consultancy which specializes in healthcare, direct marketing and strategic planning. From 2005 to 2008, Mr. Sandino also was the Chief Marketing Strategist for Integrated Marketing Solutions, Inc. and assisted clients in establishing brand recognition.
Harry H.S. Fong, Ph.D.
Advisor for Product and Intellectual
Property Development Prof. Fong is also involved with issues concerning the standardization of botanical dietary supplements and traditional herbal medicines; of monographing medicinal plants; and of evidence-based traditional herbal medicine. Prof. Fong is the author and co-author of more than 255 original research papers, several book chapters and review articles and is co-editor of a book series on Chinese medicine as well as a contributor to World Health Organization monographs and guidelines on medicinal plants. He has served as a consultant to a number of herbal medicine and dietary supplements companies and is founder and president of NatProPharm Services, Ltd, a natural products pharmaceuticals research and development and consulting services company.
Jim Metropoulos, MD
From 2003 to 2006, Dr. Metropoulos was
Co-President of Sudler & Hennessey. In this
role he helped increase revenues from $45
million to $97 million per year while
increasing the client base from 12 to 35. In
addition, he established publication
planning and managed care practices, managed
a second network agency (Sentrix NJ),
established joint ventures with a contract
research organization, Tablet PC firm, and
managed care specialty firm and participated
in the acquisition of a sales training and
medical education company. From 2006 to
2007, Dr. Metropoulos was President and CEO
of Euro RSCG Life Worldwide, the global
healthcare communications network of Euro
RSCG Worldwide and Havas, Inc.
Bob Adler
Fernando Chávarri Fernando Chávarri holds a law degree from the Universidad Complutense de Madrid, is a practicing lawyer by the Ilustre Colegio de Madrid (Chartered 25,191), and Master in Community Law from the Complutense University of Madrid. Since 1986, he has been a member of the National Graphical Association of Press and TV (No.1062). Mr. Chávarri has performed duties of Deputy Director in the Regional Central Bank of Europe (Madrid) and three years working as Financial Advisor-Sales at Barclays Bank (Madrid). Since 1998, he has had multiple roles as an Attorney Advisor and Personal Assistant in business companies owned by Mr. Benedi’s holding companies (Property Development, Leisure Industry, Finance activities, etc.).
Ricardo Xalma Recent Key Press Releases Monday, October 5, 2009 – Caleco Pharma Corp. Announces Engagement of Cosmetic Project Management - BELLINGHAM, WASHINGTON - (MARKET WIRE) - Caleco Pharma Corp. (the "Company") (OTCBB: CAEH)(FRANKFURT: T3R)(WKN: AON9YO) (www.calecopharmacorp.com) is pleased to announce that it has developed or in the process of developing its Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner, LamiriHair Tonic) and Natural Skin Care Products (LamiriGel and LamiriCreme). The formulations of these products are derived from the Company's proprietary technology that it refers to as the "Liver Health Formula". In connection with the development of these products, the Company has engaged Cosmetic Project Management, a Spanish corporation engaged in the business of the formulation, development and commercialization of cosmetic products, to assist it in formulating, developing and commercializing its Natural Hair Care Products and Natural Skin Care Products. In particular, Cosmetic Project Management has agreed to do the following: (a) Produce samples for each of the Company's Natural Hair Care Products and Natural Skin Care Products. (b) Provide the Company with a feasibility study on the Company's Natural Hair Care Products and Natural Skin Care Products. (c) Design product packaging and develop an advertising plan for the Company's Natural Hair Care Products and Natural Skin Care Products. (d) Assist the Company in selecting a manufacturer in order to ensure good manufacturing practice guidelines are met. (e) Assist the Company in preparing and filing a product dossier for each of the Company's Natural Hair Care Products and Natural Skin Care Products. In consideration for these services, the Company has agreed to pay EUR 20,100 to Cosmetic Project Management, of which EUR 10,050 has already been paid as a deposit. The balance of the payment is to be paid immediately prior to the production of the samples. The Company anticipates that it will use the samples of its Natural Hair Care Products and Natural Skin Care Products for clinical studies purposes. These clinical studies will assist the Company in determining whether there are any dermatological health benefits for hair and skin through the use of its Natural Hair Care Products and Natural Skin Care Products. Thursday, October 1, 2009 – Caleco Pharma Corp. Announces Signing of Letter of Intent with Caleco Pharma Europe S.L. - Caleco Pharma Corp. is pleased to announce that on September 30, 2009 the Company signed a letter of intent (the "Letter of Intent") with Caleco Pharma Europe S.L. ("SL"), a Spanish Corporation. The Letter of Intent sets out the proposed terms of a License agreement whereby SL has agreed to acquire an exclusive license in Continental Europe to market and exploit certain products the Company has developed or is developing. The term of the proposed license is for a period of twenty (20) years. The products under the proposed license include the Company's Natural Hair Care Products (LamiriShampoo, LamiriHair Conditioner and LarimiHair Tonic), Natural Skin Products (LamiriGel and LamiriCreme), Energy Drinks (KTKin) and Chewing Gum (KTK Chewing Gum and KTKids Children Chewing Gum) (the "Products"). The formulations of these products are derived from the Company's proprietary technology that it refers to as the "Liver Health Formula". Under the terms of the proposed license agreement, SL will be required to do the following: (a) deliver to the Company of 10% of the shares of SL which will be delivered no later than 30 days from the execution of the proposed license agreement; (b) pay a royalty of five percent (5%) of its gross sales of the Products to Caleco; and (c) achieve annual gross revenues of: (i) $3,000,000 from the sale of the Company's product during the period of July 31, 2012 to July 30, 2013; (ii) $5,000,000 from the sale of the Company's product during the period of July 31, 2013 to July 30, 2014; and (iii) $12,000,000 from the sale of the Company's product during the period of July 31, 2014 to July 30, 2015. If SL is unable to achieve these revenues, the Company will have the right to terminate the proposed license agreement. Under the proposed license agreement, subject to the approval of the Company, SL will have the right to sub-license the Products in continental Europe. The Company or SL will also have the right to assign its entire interest in the proposed license agreement subject to the following: (a) the assignment is subject to the mutual agreement of both the Company and SL on the conditions of the proposed assignment; and (b) any refusal of approval by the Company will not be considered reasonable if the transaction that is the subject of the refusal is in accordance with internationally accepted standards for the licensing of products. The terms of the Letter of Intent are non-binding and will expire unless a formal agreement is entered into by November 29, 2009. The above is subject to the conclusion of a formal agreement. There is no assurance that a formal agreement will be concluded or that the terms will not change from those described above. Wednesday, September 30, 2009 – Caleco Pharma Corp. – Corporate Update -Caleco Pharma Corp. is pleased to announce a corporate update with respect to its business activities. Over the course of the past 60 days, several meetings and presentations have occurred between the Company's management and various corporations, private and public, to further the development of our proprietary technology known as our "Liver Health Formula" and the expansion of our marketing and commercialization efforts of our Liver Health Formula. As a result of these meetings, we have identified several business opportunities. As previously announced, we signed a letter of intent (the "Letter of Intent") with Puleva Biotech S.A. ("Biotech"), a publicly listed Spanish Corporation engaged in the business of research, development and commercialization of health related products. The Letter of Intent sets out the terms of a proposed license agreement whereby we have agreed to acquire an exclusive license to market and exploit Biotech's patented probiotic bacteria product known as Hereditum in the United States, Canada and Mexico. We have also submitted proposals to form alliances in order to provide for the development and distribution of products derived from our Liver Health Formula. We plan to provide further corporate updates to our shareholders and the investment community upon our forming additional relationships and completing additional letters of understanding. We will continue to explore adding industry professionals and experts who have experience in the areas of clinical research, product development, marketing and distribution to our Board of Directors and will continue to seek out strategic relationships with these individuals. We plan on continuing the development of our proprietary technology as naturally sourced health supplements and for dermatological applications. Thursday, September 10, 2009 – Caleco Pharma Corp. Announces Signing of Letter of Intent with Puleva Biotech S.A. - Caleco Pharma Corp. is pleased to announce that it has signed a letter of intent (the "Letter of Intent") with Puleva Biotech S.A. ("Biotech"), a publicly listed Spanish Corporation engaged in the business of research, development and commercialization of health related products. The Letter of Intent sets out the proposed terms of the license agreement whereby the Company will acquire an exclusive license to market and exploit Biotech's patented probiotic bacteria product known as Hereditum in the United States, Canada and Mexico. Under the terms of the proposed license agreement, the Company will be required to do the following: (a) pay 1,000,000 Euros (the "Cash Purchase Price") to Biotech on the later of 120 days from execution of the proposed license agreement or five business days following delivery to the Company of a Generally Recognized as Safe ("GRAS") authorization from the U.S. Food and Drug Administration (the "FDA"); (b) pay a royalty of 5% of the Company's gross sales of Hereditum to Biotech; (c) conduct a clinical trial, at the Company's expense, on the effectiveness of Hereditum in preventing Mastitis. If the clinical trial fails to establish a substantial difference between Hereditum and a placebo, the Company may terminate the proposed license agreement and be entitled to a payment of 1,000,000 Euros from Biotech; (d) achieve sales of Hereditum at reasonable commercial levels within three years following payment of the Cash Purchase Price. If the Company is unable to obtain sales at reasonable commercial levels, the license will become a non-exclusive license and Biotech may grant other licenses within the United States, Canada and Mexico; and (e) achieve gross revenues of $40,000,000 from the sale of Hereditum within five years following payment of the Cash Purchase Price. If the Company is unable to achieve these revenues, Biotech will have the right to terminate the proposed license agreement. Under the proposed license agreement, subject to the approval of Biotech, the Company will have the right to sub-license Hereditum in the United States, Canada and Mexico. The Company will also have the right to assign its entire interest in the proposed license agreement subject to the following: (a) if the assignment is for a combination of a cash payment and royalties, the Company will be entitled to retain the cash payment and 50% of the royalty. If the royalty is less than 5%, Biotech will be entitled to a minimum royalty of 2.5% and the Company will be entitled to the balance of the royalty; and (b) if the assignment is for cash consideration only, the Company will be entitled to retain 70% of the cash payment and Biotech will be entitled to 30% of the cash payment. The terms of the Letter of Intent are non-binding and will expire unless a formal agreement is entered into by October 30, 2009. The above is subject to the conclusion of a formal agreement. There is no assurance that a formal agreement will be concluded or that the terms will not change from those described above. Green Baron Conclusion If a company is going to test the OTC market first with a naturally sourced product, it had better be able to differentiate itself from the rest. Caleco Pharma has already conducted a scientific test with absolutely astounding results. It has caught the interest of harsh skeptics that are now believers. The Green Baron Report has had a chance to discuss marketing plans with Caleco’s very own Jim Sandino. Mr. Sandino is considered by some to be a marketing genius after his work on Rogaine and Lamisil. His experience is ideally suited for Caleco, and we believe he will create significant revenues through his use of highly efficient and effective marketing strategies and tactics. Perhaps the best way to understand the potential of its products and their effectiveness is to listen to our interviews with the Company’s experts that will be coming soon. In the meantime, we believe all members should get a piece of CAEH before its next move up. At the current price near .18 per share, we see it as an ideal time to accumulate. Company Contact: Caleco Pharma Corp.
John Boschert
President
(360) 306-1133
www.calecopharmacorp.com
|
||||
|
. |
||||
